Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
NCT05739123
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pregnancy Related
- Pregnancy Complications
- Pregnancy, High Risk
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 0 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Sumitomo Pharma Switzerland GmbH
- Last updated on ClinicalTrials.gov
- August 19, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- PPD · Wilmington, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.